08-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-26 Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
01-23 Bavarian Nordic A/S Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil CI
12-10 Psivant Therapeutics, Inc. announced that it has received $47.5 million in funding from YK Bioventures, Samsara BioCapital LLC, Roivant Sciences Ltd., LSV Capital Management, LLC, Eurofarma Laboratórios S.A. and other investors CI
11-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
21/10/25 Mentis Care, Inc Appoints Hassan Kotob as Chief Executive Officer CI
21/10/25 SK Biopharmaceuticals Co., Ltd. Launches Joint Venture with Eurofarma for Ai-Based Epilepsy Management Platform CI
21/08/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
26/03/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
16/03/25 Eurofarma Laboratórios S.A. acquired 60% stake in Klibra Agenciamento de Marcas e Negócios for approximately BRL 160 million. CI
14/11/24 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
Manager TitleAgeSince
Chief Executive Officer - 22/11/2021
Investor Relations Contact 40 22/11/2021
Director TitleAgeSince
Chairman - 22/11/2021
Director/Board Member 57 22/11/2021
Director/Board Member 50 31/12/2018
Date Insider Type Main position Quantity % Market Cap.
10/01/25 Buy 1,644,236 0.1665%
04/12/24 Sell 15,405,639 1.5600%
04/12/24 Buy 15,405,639 1.5600%

Financials

2024 2025
Net sales 10.97B 2.11B 1.82B 1.7B 1.55B 2.93B 201B 2.94B 20.2B 7.88B 102B 7.91B 7.74B 337B 12.48B 2.4B 2.06B 1.94B 1.77B 3.33B 229B 3.34B 22.97B 8.96B 116B 9B 8.8B 383B
Net income 117M 22.52M 19.41M 18.19M 16.61M 31.29M 2.15B 31.39M 216M 84.22M 1.09B 84.55M 82.71M 3.6B 571M 110M 94.55M 88.65M 80.93M 152M 10.49B 153M 1.05B 410M 5.29B 412M 403M 17.55B
Net Debt - -
  1. Stock Market
  2. Stocks
  3. EUFA3 Stock